Zoetis Inc. Files 8-K Report

TL;DR

Zoetis filed an 8-K, likely with financial updates. Watch for details.

AI Summary

On August 11, 2025, Zoetis Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating potential updates or disclosures related to the company's financial performance or significant business developments. No specific financial figures or new events were detailed in the provided excerpt.

Why It Matters

This filing signals that Zoetis Inc. is providing updated information to the SEC, which could include material business events or financial disclosures relevant to investors.

Risk Assessment

Risk Level: low — The filing is a standard regulatory report (8-K) and does not, in itself, indicate any immediate or specific risks.

Key Players & Entities

• Zoetis Inc. (company) — Registrant
• August 11, 2025 (date) — Date of earliest event reported
• 10 Sylvan Way, Parsippany, NJ 07054 (address) — Principal executive offices

FAQ

From the Filing

0001193125-25-182451.txt : 20250818 0001193125-25-182451.hdr.sgml : 20250818 20250818114310 ACCESSION NUMBER: 0001193125-25-182451 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 20 CONFORMED PERIOD OF REPORT: 20250811 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250818 DATE AS OF CHANGE: 20250818 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zoetis Inc. CENTRAL INDEX KEY: 0001555280 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 460696167 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35797 FILM NUMBER: 251226965 BUSINESS ADDRESS: STREET 1: 10 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-822-7000 MAIL ADDRESS: STREET 1: 10 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 8-K 1 d899078d8k.htm 8-K 8-K false 0001555280 0001555280 2025-08-11 2025-08-11     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 11, 2025     Zoetis Inc. (Exact name of registrant as specified in its charter)       Delaware   001-35797   46-0696167 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   10 Sylvan Way , Parsippany , NJ   07054 (Address of principal executive offices)   (Zip Code) (973) 822-7000 (Registrant’s telephone number, including area code) Not Applicable (Former Name or Former Address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.01 per share   ZTS   New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 8.01. Other Events. On August 11, 2025, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”), between the Company and the underwriters named therein, for the issuance and sale by the Company of $850,000,000 aggregate principal amount of its 4.150% Senior Notes due 2028 (the “2028 Notes”) and $1,000,000,000 aggregate principal amount of its 5.000% Senior Notes due 2035 (the “2035 Notes” and, together with the 2028 Notes, the “Notes”). The Notes were issued pursuant to an indenture, dated January 28, 2013, between the Company and Deutsche Bank Trust Company Americas (the “Base Indenture”), as supplemented by the seventh supplemental ind